Oncology

Latest News

Grafapex Approved for Reduced-Intensity Stem Cell Transplants in AML and MDS Patients
Grafapex Approved for Reduced-Intensity Stem Cell Transplants in AML and MDS Patients

February 6th 2025

Treosulfan (Grafapex) was approved in Canada in June 2021 for the same use and is marketed under the brand name Trecondyv.

FDA Approves First BTK Inhibitor as First-Line Therapy for Mantle Cell Lymphoma
FDA Approves First BTK Inhibitor as First-Line Therapy for Mantle Cell Lymphoma

January 27th 2025

Investigational Breast Cancer Drug Demonstrates Potential Benefit in Treating AML and Other Blood Cancers
Investigational Breast Cancer Drug Demonstrates Potential Benefit in Treating AML and Other Blood Cancers

January 16th 2025

ADC Loncastuximab Tesirine Induces High Response Rates in Patients with High-Risk Follicular Lymphoma and Marginal Zone Lymphoma
ADC Loncastuximab Tesirine Induces High Response Rates in Patients with High-Risk Follicular Lymphoma and Marginal Zone Lymphoma

January 14th 2025

Progress Made for Gastric Cancer with FDA Approval of Tevimbra
Progress Made for Gastric Cancer with FDA Approval of Tevimbra

January 6th 2025

More News

© 2025 MJH Life Sciences

All rights reserved.